| __timestamp | ADMA Biologics, Inc. | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4823869 | 7461000 |
| Thursday, January 1, 2015 | 6745968 | 11960000 |
| Friday, January 1, 2016 | 8494742 | 13108000 |
| Sunday, January 1, 2017 | 18092835 | 17501000 |
| Monday, January 1, 2018 | 22502922 | 22472000 |
| Tuesday, January 1, 2019 | 25910757 | 24286000 |
| Wednesday, January 1, 2020 | 35050817 | 29689000 |
| Friday, January 1, 2021 | 42896889 | 38837000 |
| Saturday, January 1, 2022 | 52458024 | 47489000 |
| Sunday, January 1, 2023 | 59020000 | 53379000 |
Igniting the spark of knowledge
In the competitive landscape of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, ADMA Biologics, Inc. and Xencor, Inc. have shown distinct trends in their SG&A expenditures. From 2014 to 2023, ADMA Biologics saw a staggering increase of over 1,100% in their SG&A costs, peaking at approximately $59 million in 2023. In contrast, Xencor's SG&A expenses grew by about 615%, reaching around $53 million in the same year. While both companies have seen significant increases, ADMA's expenses have grown at a faster rate, suggesting a more aggressive expansion strategy. Investors and stakeholders should consider these trends when evaluating the operational efficiency and strategic direction of these biotech firms.
Selling, General, and Administrative Costs: Eli Lilly and Company vs Xencor, Inc.
Sanofi and Xencor, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of BeiGene, Ltd. and Xencor, Inc.
Breaking Down SG&A Expenses: Incyte Corporation vs Xencor, Inc.
Intra-Cellular Therapies, Inc. vs ADMA Biologics, Inc.: SG&A Expense Trends
Intra-Cellular Therapies, Inc. vs Xencor, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Ascendis Pharma A/S vs Xencor, Inc. Trends and Insights
Halozyme Therapeutics, Inc. or ADMA Biologics, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Axsome Therapeutics, Inc. vs ADMA Biologics, Inc.
Axsome Therapeutics, Inc. or Xencor, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of ADMA Biologics, Inc. and Mesoblast Limited
Operational Costs Compared: SG&A Analysis of Viking Therapeutics, Inc. and Xencor, Inc.